Eidogen-Sertanty Licenses TIP to the FDA
Eidogen-Sertanty licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

SAN DIEGO, CA, December 08, 2009 /24-7PressRelease/ -- Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

Under the terms of the license, scientists within NCTR will have access to the complete TIP structural knowledgebase via onlineTIP as well as access to the TIP/Workgroup technology for internal research. Eidogen-Sertanty will also participate in several NCTR-led projects including the multi-year PADRE project (MAQC-IV), which is focusing on the modeling of drug-protein interactions to identify new genetic variations that may lead to serious adverse drug reactions.

"We're extremely pleased to have licensed the TIP technology to the FDA/NCTR," said Dr. Steven Muskal, Eidogen-Sertanty's Chief Executive Officer. "We very much look forward to having a positive impact in the FDA's effort to predict serious adverse drug reactions at the individual patient level."

Eidogen-Sertanty contact:

Steve Muskal
760-651-2885
pr@eidogen-sertanty.com

Press Release Contact Information:

Steven Muskal
Eidogen-Sertanty
CEO
3460 Marron Rd Ste 103-475
Oceanside, CA
USA 92056
Voice: 760-651-2885
Fax: 775-822-1721
Website: Visit Our Website